We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ingevity's (NGVT) Earnings and Sales Miss Estimates in Q3
Read MoreHide Full Article
Ingevity Corporation (NGVT - Free Report) recorded third-quarter 2023 profits of $25.2 million or 69 cents per share, down from $75.4 million or $1.98 per share in the year-ago quarter.
Excluding one-time items, adjusted earnings in the quarter were $1.21 per share, down from $2.09 a year ago. The figure missed the Zacks Consensus Estimate of $1.22.
Revenues fell 7.5% year over year to $446 million in the quarter, missing the Zacks Consensus Estimate of $466.4 million. Lower volumes due to weak industrial demand mainly affected Advanced Polymer Technologies and the Industrial Specialties business lines, partly offset by increased North America and Asia sales and higher pricing in the Pavement Technologies business line.
Ingevity Corporation Price, Consensus and EPS Surprise
The Performance Chemicals division generated revenues of $256 million in the reported quarter, down around 4% year over year. The reported figure was lower than the consensus estimate of $264 million.
Revenues in the Performance Materials unit rose around 2% year over year to $147.2 million. The figure was higher than the consensus estimate of $142 million.
Sales in the Advanced Polymer Technologies segment were down 38% at $42.8 million. It was below the consensus estimate of $61 million.
Financials
Operating cash flow in the third quarter was $106.9 million, and free cash flow came in at $73.4 million. This was mostly due to greater inventory levels brought on both higher CTO prices and lower demand for rosin. There were no share repurchases during the quarter, and $353.4 million of the $500 million Board authorization from July 2022 is still available. Due to higher borrowing for the Ozark acquisition in the fourth quarter of 2022, net leverage was 3.2 times.
Outlook
As it enters the fourth quarter, the year-long soft industrial demand environment does not seem to be improving, therefore volume weakness is anticipated to persist, NGVT noted. Furthermore, price pressure is increasing as the weakness continues, especially in cyclical areas like adhesives and oilfield. The company cut its adjusted EBITDA outlook for the full year to between $375 million and $390 million due to growing CTO expenses in the fourth quarter and the failure to recover costs through pricing adjustments.
Price Performance
Shares of Ingevity have plunged 39.6% in a year against a 12.8% rise of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Ingevity currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the basic materials space include Equinox Gold Corp. (EQX - Free Report) , Koppers Holdings Inc. (KOP - Free Report) and The Andersons Inc. (ANDE - Free Report) .
Equinox has a projected earnings growth rate of 90% for the current year. It currently carries a Zacks Rank #2 (Buy). Equinox delivered a trailing four-quarter earnings surprise of roughly 18.1%, on average. The stock is up around 54.1% in a year. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Koppers has a projected earnings growth rate of 7.5% for the current year. It currently carries a Zacks Rank #2. Koppers delivered a trailing four-quarter earnings surprise of roughly 21.7%, on average. The stock is up around 52.8% in a year.
Andersons currently carries a Zacks Rank #1. The stock has gained roughly 38.9% in the past year. ANDE beat the Zacks Consensus Estimate in each of the last four quarters. It delivered a trailing four-quarter earnings surprise of 64.4%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ingevity's (NGVT) Earnings and Sales Miss Estimates in Q3
Ingevity Corporation (NGVT - Free Report) recorded third-quarter 2023 profits of $25.2 million or 69 cents per share, down from $75.4 million or $1.98 per share in the year-ago quarter.
Excluding one-time items, adjusted earnings in the quarter were $1.21 per share, down from $2.09 a year ago. The figure missed the Zacks Consensus Estimate of $1.22.
Revenues fell 7.5% year over year to $446 million in the quarter, missing the Zacks Consensus Estimate of $466.4 million. Lower volumes due to weak industrial demand mainly affected Advanced Polymer Technologies and the Industrial Specialties business lines, partly offset by increased North America and Asia sales and higher pricing in the Pavement Technologies business line.
Ingevity Corporation Price, Consensus and EPS Surprise
Ingevity Corporation price-consensus-eps-surprise-chart | Ingevity Corporation Quote
Segmental Review
The Performance Chemicals division generated revenues of $256 million in the reported quarter, down around 4% year over year. The reported figure was lower than the consensus estimate of $264 million.
Revenues in the Performance Materials unit rose around 2% year over year to $147.2 million. The figure was higher than the consensus estimate of $142 million.
Sales in the Advanced Polymer Technologies segment were down 38% at $42.8 million. It was below the consensus estimate of $61 million.
Financials
Operating cash flow in the third quarter was $106.9 million, and free cash flow came in at $73.4 million. This was mostly due to greater inventory levels brought on both higher CTO prices and lower demand for rosin. There were no share repurchases during the quarter, and $353.4 million of the $500 million Board authorization from July 2022 is still available. Due to higher borrowing for the Ozark acquisition in the fourth quarter of 2022, net leverage was 3.2 times.
Outlook
As it enters the fourth quarter, the year-long soft industrial demand environment does not seem to be improving, therefore volume weakness is anticipated to persist, NGVT noted. Furthermore, price pressure is increasing as the weakness continues, especially in cyclical areas like adhesives and oilfield. The company cut its adjusted EBITDA outlook for the full year to between $375 million and $390 million due to growing CTO expenses in the fourth quarter and the failure to recover costs through pricing adjustments.
Price Performance
Shares of Ingevity have plunged 39.6% in a year against a 12.8% rise of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Ingevity currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the basic materials space include Equinox Gold Corp. (EQX - Free Report) , Koppers Holdings Inc. (KOP - Free Report) and The Andersons Inc. (ANDE - Free Report) .
Equinox has a projected earnings growth rate of 90% for the current year. It currently carries a Zacks Rank #2 (Buy). Equinox delivered a trailing four-quarter earnings surprise of roughly 18.1%, on average. The stock is up around 54.1% in a year. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Koppers has a projected earnings growth rate of 7.5% for the current year. It currently carries a Zacks Rank #2. Koppers delivered a trailing four-quarter earnings surprise of roughly 21.7%, on average. The stock is up around 52.8% in a year.
Andersons currently carries a Zacks Rank #1. The stock has gained roughly 38.9% in the past year. ANDE beat the Zacks Consensus Estimate in each of the last four quarters. It delivered a trailing four-quarter earnings surprise of 64.4%, on average.